A 52-week, Multi-center, Open-label Study of the Safety and Tolerability of Agomelatine Sublingual Tablets in Patients With Major Depressive Disorder (MDD).

Trial Profile

A 52-week, Multi-center, Open-label Study of the Safety and Tolerability of Agomelatine Sublingual Tablets in Patients With Major Depressive Disorder (MDD).

Discontinued
Phase of Trial: Phase III

Latest Information Update: 13 Mar 2013

At a glance

  • Drugs Agomelatine (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 06 Nov 2011 Planned End Date changed from 1 Jul 2012 to 1 Nov 2011 as reported by ClinicalTrials.gov.
    • 06 Nov 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 11 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top